✦ LIBER ✦

858 SAFETY ANALYSIS OF THE ADVANCED RENAL CELL CARCINOMA SORAFENIB (ARCCS) STUDY, AN EXPANDED ACCESS PROGRAM

✍ Scribed by R. Bukowski; R. Figlin; W. Stadler

Book ID: 119618175
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 328 KB
Volume: 6
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(07)60853-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SORAFENIB THERAPY IN THE MANAGEMENT OF A

SORAFENIB THERAPY IN THE MANAGEMENT OF ADVANCED RENAL CELL CARCINOMA WITH BRAIN METASTASES: RESULTS FROM THE ARCCS EXPANDED ACCESS PROGRAM

✍ C.A. Henderson; R.M. Bukowski; W.M. Stadler; J.P. Dutcher; T.L. Kindwall-Keller; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Safety and efficacy results of the advan

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

✍ Walter M. Stadler; Robert A. Figlin; David F. McDermott; Janice P. Dutcher; Jenn 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

## Abstract ## BACKGROUND: The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval. ## METHODS: In this nonrandomized, open‐label expanded access program, 2504 patients from the United St

7132 Safety and efficacy of sorafenib in

7132 Safety and efficacy of sorafenib in patients with advanced renal cell carcinoma (RCC) with varying histologies: results from the phase 3, open access study of sorafenib in European patients with advanced RCC (EU-ARCCS)

✍ Bokemeyer, C.; Gore, M.; Bracarda, I.; Richel, N.; Staehler, D.; von der Maase, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Safety of Everolimus by Treatment Durati

Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program

✍ van den Eertwegh, Alfonsus J.M.; Karakiewicz, Pierre; Bavbek, Sevil; Rha, Sun Yo 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 104 KB

Safety and efficacy of sunitinib for met

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

✍ Martin E Gore; Cezary Szczylik; Camillo Porta; Sergio Bracarda; Georg A Bjarnaso 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 143 KB

SAFETY AND EFFICACY OF SUNITINIB IN META

SAFETY AND EFFICACY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (mRCC): PRELIMINARY ASSESSMENT OF AN ITALIAN EXPANDED-ACCESS PROGRAM (EAP) WITH SUBPOPULATION ANALYSIS

✍ Sternberg, Cora N; Porta, Camillo; Bracarda, Sergio; Carteni, Giacomo; Re, Giova 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 191 KB